0001609351-17-000125.txt : 20171129 0001609351-17-000125.hdr.sgml : 20171129 20171129170845 ACCESSION NUMBER: 0001609351-17-000125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171128 FILED AS OF DATE: 20171129 DATE AS OF CHANGE: 20171129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: High Katherine A CENTRAL INDEX KEY: 0001631248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36819 FILM NUMBER: 171229143 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spark Therapeutics, Inc. CENTRAL INDEX KEY: 0001609351 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462654405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 888-772-7560 MAIL ADDRESS: STREET 1: 3737 MARKET STREET STREET 2: SUITE 1300 CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 wf-form4_151199331155712.xml FORM 4 X0306 4 2017-11-28 0 0001609351 Spark Therapeutics, Inc. ONCE 0001631248 High Katherine A C/O SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA PA 19104 1 1 0 0 See Remarks Common Stock 2017-11-28 4 M 0 5000 3.45 A 215000 D Common Stock 2017-11-28 4 S 0 3500 70.91 D 211500 D Common Stock 2017-11-28 4 S 0 1500 72.27 D 210000 D Stock Option (right to buy) 3.45 2017-11-28 4 M 0 5000 0 D 2024-07-02 Common Stock 5000.0 73249 D The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.54 to $71.25, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. President and Head of Research and Development /s/ Joseph W. La Barge, attorney-in-fact for Katherine A. High 2017-11-29